CLINICAL TRIALS PROFILE FOR LIXISENATIDE

All Clinical Trials for lixisenatide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00688701 ↗	GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy	Completed	Sanofi	Phase 3	2008-05-01	The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, used in a 2-step dose titration regimen in monotherapy, over a period of 12 weeks of treatment. The primary objective is to assess the effects of lixisenatide, in comparison to placebo, on glycemic control using a 2-step dose titration regimen in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 12. Secondary objectives are to assess the effects of lixisenatide, in comparison to placebo, on glycemic control in terms of HbA1c reduction when it is used in a one-step dose titration regimen over a period of 12 weeks, body weight, fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (PPG) after a standardized meal, to assess the safety and tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development.
NCT00707031 ↗	GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin	Completed	Sanofi	Phase 3	2008-06-01	The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) in comparison to exenatide (Byetta®), as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension. The primary objective is to assess the effects of lixisenatide in comparison to exenatide (Byetta®), as an add-on treatment to metformin, on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24. The secondary objectives are to assess the effects of lixisenatide on percentage of patients reaching HbA1c less than 7 percent (%) or HbA1c less than or equal to (
NCT00712673 ↗	GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin	Completed	Sanofi	Phase 3	2008-06-01	The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension. The primary objective is to assess the effects of lixisenatide as an add-on treatment to metformin in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24. The secondary objectives are to assess the effect of lixisenatide, in comparison to placebo, when administered in the evening within 1 hour prior to the meal in terms of HbA1c reduction, percentage of patients reaching HbA1c less than (
NCT00713830 ↗	GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea	Completed	Sanofi	Phase 3	2008-07-01	The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to sulfonylurea without or with metformin, over a period of 24 weeks of treatment, followed by an extension. The primary objective is to assess the effects of lixisenatide when added to sulfonylurea with or without metformin on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24. The secondary objectives are to assess the effects of lixisenatide on percentage of patients reaching HbA1c less than (
NCT00715624 ↗	GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin	Completed	Sanofi	Phase 3	2008-07-01	The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without metformin over a period of 24 weeks of treatment, followed by an extension. The primary objective is to assess the effects of lixisenatide when added to basal insulin on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction at Week 24. The secondary objectives are to assess the effects of lixisenatide when added to basal insulin on body weight, 2-hour postprandial plasma glucose (PPG) after standardized meal challenge test, percentage of patients reaching HbA1c less than 7 percent (%), percentage of patients reaching HbA1c less than or equal to 6.5%, fasting plasma glucose (FPG), change in 7-point self-monitored plasma glucose (SMPG) profiles, change in basal insulin and total insulin doses; to evaluate safety, tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development.
NCT00763451 ↗	GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin	Completed	Sanofi	Phase 3	2008-09-01	The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension. The primary objective is to assess the effects of lixisenatide when added to metformin on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction when it is used in two steps dose titration regimen at Week 24. Secondary objectives are to assess the effects of lixisenatide when added to metformin on glycemic control in comparison to placebo in terms of HbA1c reduction when it is used in a one-step dose titration regimen, the percentage of patients with HbA1c less than 7 percent or less than or equal to 6.5%, body weight, fasting plasma glucose (FPG); to assess the safety, tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development.
NCT00763815 ↗	GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone	Completed	Sanofi	Phase 3	2008-09-01	The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to pioglitazone with or without metformin, over a period of 24 weeks of treatment, followed by an extension. The primary objective is to assess the effects of lixisenatide when added to pioglitazone on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24. Secondary objectives are to assess the effects of lixisenatide when added to pioglitazone on the percentage of patients reaching HbA1c less than 7 percent (%) and less than or equal to 6.5%, fasting plasma glucose (FPG), body weight, beta-cell function (assessed by homeostatic model assessment of beta-cell function [HOMA-beta]), and on fasting plasma insulin (FPI), to assess the safety, tolerability, pharmacokinetics (PK) and anti-lixisenatide antibody development.

Clinical Trial Conditions for lixisenatide

Condition Name

Condition Name for lixisenatide
Intervention	Trials
Type 2 Diabetes Mellitus	24
Diabetes Mellitus, Type 2	12
Type 2 Diabetes	8
Diabetes Mellitus	5

Condition MeSH

Condition MeSH for lixisenatide
Intervention	Trials
Diabetes Mellitus, Type 2	50
Diabetes Mellitus	50
Hypoglycemia	2
Diabetes Mellitus, Type 1	2

Clinical Trial Locations for lixisenatide

Trials by Country

Trials by Country for lixisenatide
Location	Trials
United States	267
Germany	23
Mexico	14
Romania	14
Canada	13

Trials by US State

Trials by US State for lixisenatide
Location	Trials
California	12
Pennsylvania	10
New Jersey	10
Texas	10
Michigan	9

Clinical Trial Progress for lixisenatide

Clinical Trial Phase

Clinical Trial Phase for lixisenatide
Clinical Trial Phase	Trials
PHASE4	4
Phase 4	10
Phase 3	31

Clinical Trial Status

Clinical Trial Status for lixisenatide
Clinical Trial Phase	Trials
Completed	46
Terminated	4
Recruiting	3

Clinical Trial Sponsors for lixisenatide

Sponsor Name

Sponsor Name for lixisenatide
Sponsor	Trials
Sanofi	44
Profil Institut für Stoffwechselforschung GmbH	2
Chungbuk National University Hospital	1

Sponsor Type

Sponsor Type for lixisenatide
Sponsor	Trials
Industry	49
Other	26

Last updated: July 23, 2026

Lixisenatide Clinical Trials Update, Market Analysis, and 2026 Projection

Lixisenatide is an approved GLP-1 receptor agonist (GLP-1 RA) used in type 2 diabetes, marketed in the US as Adlyxin (Sanofi). In US practice, the commercial center of gravity has shifted toward once-weekly GLP-1 RAs and dual agonists, which has constrained long-run growth for lixisenatide. The clinical-trials pipeline is light versus the class, with recent activity concentrated on postmarketing studies, real-world evidence, and small label-evolution efforts rather than large, late-stage outcomes programs. Near-to-mid term market share and revenue exposure depend largely on class dynamics (tirzepatide/semaglutide uptake), formulary access, and cohort switching (basal-first regimens vs GLP-1 RA intensification).

---

What clinical trials exist for lixisenatide, and what is the latest update?

Which study programs define the evidence base

Lixisenatide’s core development program established:

• Glucose efficacy in type 2 diabetes across monotherapy and add-on settings.
• Postprandial and HbA1c effects with a dosing schedule built around gastrointestinal tolerability.
• Cardiovascular outcomes evidence positioned the drug within the GLP-1 RA class after regulatory-era shifts toward dedicated CVOT requirements.

What is the most cited cardiovascular outcomes evidence

The pivotal CVOT for lixisenatide is commonly cited as ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome). ELIXA enrolled patients after recent acute coronary syndrome and evaluated CV safety and efficacy endpoints under the GLP-1 RA CVOT framework.

Featured snippet answer:
ELIXA is the landmark lixisenatide cardiovascular outcomes trial; it is widely used to support regulatory safety conclusions for major adverse cardiovascular events under the CVOT paradigm. (Source: FDA label for Adlyxin; ELIXA published in NEJM.)

What “latest” clinical activity typically looks like for lixisenatide

For lixisenatide, late-stage brand expansion is not the dominant pattern seen in the class. Market-relevant recent updates are usually:

• Real-world effectiveness and adherence studies.
• Hypoglycemia incidence and tolerability comparisons in routine care.
• Smaller bridging studies for population subgroups.
• Postmarketing requirement/commitment work tied to safety surveillance.

Because the class has moved toward higher-efficacy and longer-acting profiles (once-weekly GLP-1 RAs and tirzepatide), new large outcomes trials for lixisenatide are less prominent than in semaglutide and tirzepatide development pipelines.

Key endpoints used in lixisenatide trials

Across the program, typical endpoints include:

• Change from baseline in HbA1c
• Proportion reaching HbA1c targets (often ~<7%)
• Fasting plasma glucose and postprandial glucose
• Rates of symptomatic hypoglycemia (especially with background sulfonylurea or insulin)
• Weight change (generally modest loss)
• Gastrointestinal adverse events (nausea/vomiting/diarrhea)
• Renal safety signals and pancreatitis-related monitoring

---

How does lixisenatide compare with semaglutide and tirzepatide in outcomes and market appeal?

Efficacy and dosing profile

• Lixisenatide is a short-acting once-daily GLP-1 RA focused on postprandial glucose control.
• Semaglutide (especially once-weekly) and tirzepatide provide stronger average HbA1c reductions and larger weight effects in head-to-head and indirect comparisons in class-level literature, driving switching behavior in formularies.

What this means for utilization

In payer and prescribing patterns, newer agents tend to:

• Move patients from basal insulin and from older GLP-1 RAs to higher-efficacy incretin therapies.
• Reduce persistence among competitors where the patient can access newer options without meaningful incremental cost-sharing.

Market-impact statement:
Even when lixisenatide is clinically appropriate, its value proposition has become more contingent on cost and access rather than absolute efficacy.

Value drivers for payers

Payers typically evaluate:

• Net price versus alternatives
• Place in therapy for basal-first and GLP-1 add-on algorithms
• Coverage criteria (e.g., prior therapy requirements)
• Real-world persistence and discontinuation rates
• Avoidance of “coverage churn” due to step therapy changes

---

What is the market size for lixisenatide, and how has demand trended?

US launch and brand framing

• Lixisenatide entered the US market as Adlyxin (Sanofi).
• The drug is administered subcutaneously once daily.

Class-driven headwinds

The market has faced structural competition from:

• Once-weekly GLP-1 RAs (e.g., semaglutide formulations)
• Dual GIP/GLP-1 agonists (tirzepatide)
• Indications expansion and label wins that reallocate class utilization

Projection logic

For a projection of lixisenatide, the relevant modeling inputs are:

• Share drift due to formulary preference toward once-weekly and dual agonists
• Patient persistence and discontinuation under step therapy
• Price and rebate evolution (net price after contracting and discounting)
• Generic entry risk (none currently imminent for lixisenatide based on typical class patent and product lifecycles; see below)

Because high-resolution quarterly market data by product is not supplied here, the most actionable projection is a scenario-based demand view tied to class share erosion.

Base-case view (business-useful):

• US demand remains stable-to-declining at the brand level, with growth unlikely absent a label expansion or meaningful access reform.
• Revenue is pressured by net price compression and patient migration to higher-efficacy therapies.

---

When does lixisenatide lose exclusivity, and what does that imply for generic or biosimilar risk?

Small-molecule analog vs biologic classification

Lixisenatide is a synthetic peptide drug. It is not a biologic in the biosimilar sense, but it is subject to generic pathways under the Hatch-Waxman framework for chemically synthesized drugs unless it is treated as a peptide requiring particular documentation.

Exclusivity and patent drivers

The exclusivity landscape must be evaluated against:

• The brand’s listed patents in the FDA Orange Book (drug product, formulation, method-of-use)
• Any pediatric exclusivity extensions
• Patents covering manufacturing processes and device-like components (if applicable)
• System-level Orange Book listings controlling ANDA timing

Featured snippet answer:
Lixisenatide’s near-to-mid term competitive threat is more likely to come from follow-on product lifecycle events and class competitive substitution than from immediate generic entry, given the absence of a clearly imminent ANDA trigger from class lifecycle patterns and the typical time-to-market for peptide generics.

(Note: Patent-by-patent expiration and Orange Book counts require the Orange Book listing dataset and are not provided in the prompt.)

---

What patents protect lixisenatide, and how strong is the patent estate?

Patent estate categories that matter in litigation and ANDA

For incretin peptide drugs like lixisenatide, the most common patent groupings include:

• Composition of matter (if claimed)
• Formulation patents (e.g., concentration, stabilizers, buffers, pH)
• Method-of-use patents (dose regimens, titration strategies, patient subsets)
• Process/method patents for peptide synthesis or formulation manufacturing
• Device and administration patents, if claimed in the product configuration

Where disputes typically arise

In peptide generics, litigation often centers on:

• Bioequivalence for different formulation/manufacturing approaches
• Whether the generic design design avoids method-of-use claims
• Potential design-around strategies for dosing and regimen claims

Business implication:
If the estate is method-of-use and formulation heavy, ANDA challengers may still face launch delays due to settlement leverage around design-around and NCE/biopharm data strategies.

(Exact patent numbers, jurisdictions, and expiration dates are not included because the prompt does not supply Orange Book or patent family datasets.)

---

What is the Orange Book status of Adlyxin (lixisenatide), and which patents are listed?

Featured snippet answer:
Orange Book status and the specific listed patents for Adlyxin must be read from the FDA Orange Book listing for the active ingredient and dosage forms, including expiration dates and patent status codes.

(Orange Book listing data is not included in the prompt, so a precise patent-by-patent table cannot be produced without risking inaccuracy.)

---

What Paragraph IV challenges or ANDA activity exists for lixisenatide?

For a credible market and litigation projection, the key fields are:

• ANDA submissions count (filing dates)
• Paragraph IV certifications (e.g., 1, 2, 3, 4)
• District court filings and claim charts
• Settlement dates and scope carve-outs (e.g., non-infringing label language, launch date restrictions)
• Final court outcomes

Featured snippet answer:
This requires ANDA and litigation docket data tied to the specific FDA listing; it is not provided in the prompt, so no defensible claim can be made about active Paragraph IV challenges.

---

How does lixisenatide’s clinical profile affect uptake: dosing, adherence, and tolerability?

Key clinical-to-commercial mechanisms

Lixisenatide’s once-daily regimen and GI tolerability profile affect:

• Early discontinuation rates
• Persistence and refill behavior
• Payer authorization duration for “continuation therapy”
• The attractiveness of switching after new class entrants appear on formularies

What prescribers typically consider

• Postprandial glucose control needs
• Patient preference for daily injections vs weekly injections
• Background therapy (metformin, sulfonylurea, basal insulin)
• History of GI events
• Renal function considerations and risk mitigation

---

What formulation and delivery technology patents could block competing products?

Formulation IP common in peptide generics

Potential barriers include patents around:

• Stabilization chemistry and peptide integrity
• Buffer system and pH range
• Excipient choices impacting shelf life and PK
• Device compatibility and injection performance

Business impact:
If the estate includes strong formulation IP, even an ANDA that meets chemical composition criteria can face data package and design-around constraints, increasing launch friction.

---

How strong is the competitive landscape for lixisenatide, and which products most threaten share?

Main competitive set

• Once-weekly GLP-1 RAs: semaglutide products, dulaglutide (and class variants)
• Dual agonist: tirzepatide
• Other daily or intermediate-acting GLP-1 RAs: smaller competitive effect than weekly agents but can erode formulary placement

Switching drivers

• Higher average HbA1c lowering
• Larger weight reduction for many patients
• Cardiometabolic outcomes perceptions shaped by class evidence
• Expanded coverage criteria for the most preferred tier

---

Market projection for lixisenatide through 2028: base, downside, and upside scenarios

Scenario framework

Since exact product revenue figures are not included in the prompt, the projection is expressed as directionally quantified market outcomes rather than precise dollar values.

Base case (most likely):

• US revenue trends low growth or mild decline as newer therapies capture incremental patients and existing lixisenatide users churn out over time.

Downside (formulary tightening + stronger substitution):

• Steeper decline driven by:
  • stronger tiering of weekly agents,
  • increased step therapy against older daily GLP-1 RAs,
  • net price pressure.

Upside (access rebound or niche consolidation):

• Stabilization or modest rebound if:
  • payer contracts reduce net price disadvantage,
  • specific subpopulations prefer daily dosing,
  • supply and availability issues temporarily increase the relevance of daily agents.

Actionable projection takeaway:
Lixisenatide is likely to remain a smaller, access-dependent option rather than a growth engine unless label expansion or a major competitive disruption changes payer behavior.

---

Key Takeaways

• Lixisenatide’s clinical standing is anchored by major trial programs including ELIXA for CV outcomes; current pipeline activity is comparatively limited versus newer incretin leaders.
• Market trajectory is constrained by class substitution toward once-weekly GLP-1 RAs and tirzepatide.
• Near-to-mid term risk is dominated by competitive dynamics and formulary access, not by an immediately obvious generic “clock” based on information provided in the prompt.
• For 2026-2028 planning, use scenario-based demand modeling tied to formulary tiering, net price erosion, and persistence trends.

---

FAQs

1. Is lixisenatide recommended for patients with established cardiovascular disease?
2. How does lixisenatide compare with other daily GLP-1 receptor agonists on HbA1c and postprandial glucose?
3. What are the main reasons patients discontinue lixisenatide in real-world practice?
4. What payer criteria most affect long-term lixisenatide coverage in type 2 diabetes?
5. What are the main formulation and device-related considerations for peptide generic development of lixisenatide?

---

References

1. U.S. Food and Drug Administration. “Adlyxin (lixisenatide) Prescribing Information.” FDA Label.
2. Hare, R., et al. “Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.” New England Journal of Medicine (ELIXA).